Epigenetics Drugs Diagnostic Technologies Market Analysis

Global Epigenetics Drugs and Diagnostic Technologies Market Overview

The Epigenetics Drugs and Diagnostic Technologies Market size was valued at USD 6.75 billion in 2022 and is projected to grow from USD 8.23 billion in 2023 to USD 48.91 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 21.90% during the forecast period (2023 - 2032).

The growth of the market is driven by factors such as the increasing prevalence of chronic diseases such as Central Nervous System (CNS) diseases and oncology and the rising number of product launches & pipeline products.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Epigenetics Drugs and Diagnostic Technologies Market Trends

• Increasing prevalence of chronic diseases such as CNS diseases and oncology

The increasing incidences of chronic diseases of the central nervous system across the globe are increasing the demand for epigenetic drugs and diagnostic technologies. Epigenetics majorly treat central nervous system diseases, including Alzheimer’s, Huntington’s disease, schizophrenia, autism, and bipolar disorder. Furthermore, these drugs have low toxicity and can be given in combination with other types of drugs for better treatment. As per the World Health Organisation, there were 55 million people diagnosed with dementia globally until March 2023, and more than 60% were living in low- and middle-income (LMIC) countries.

Furthermore, according to the Alzheimer’s Association (US), approximately 6.7 million Americans aged 65 and older living with Alzheimer’s dementia in 2023.

FIGURE 2: AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA, AMERICA, 2023

Additionally, epigenetics has shown great results in treating cancer, and these drugs have the capacity to turn off Deoxyribonucleic Acid (DNA). As per GLOBOCAN 2020, breast cancer accounted for the largest share, followed by lung, colorectum, prostate, stomach, and other cancers.

Moreover, in February 2023, Cardio Diagnostics Holdings, Inc. (US) launched PrecisionCHD, the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (CHD). This artificial intelligence (AI)-driven integrated epigenetic-genetic engine assists physicians in the early detection of CHD.

Therefore, the increasing prevalence of oncology and neurology diseases, the high efficacy of epigenetic drugs to treat these diseases, and AI-driven epigenetic product launches are propelling the market growth.

Epigenetics Drugs and Diagnostic Technologies Market Segment Insights

Epigenetics Drugs and Diagnostic Technologies Drug Type Insights

The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A. The DNA methyltransferases (DNMTs) inhibitors segment dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023–2032. The major driving factor for the segments is that these inhibitors are utilized in combination with chemotherapy and immunotherapy to enhance their effectiveness.

Epigenetics Drugs and Diagnostic Technologies Diagnostic Technologies Insights

The epigenetics drugs and diagnostic technologies market segmentation, based on diagnostic technologies, is segmented into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling. The DNA methylation segment dominated the market in 2022, and histone modification analysis is projected to be the fastest-growing segment during the forecast period. The DNA methylation diagnostic tool can classify tumors and assist in early diagnosis. As per the National Academy of Science, the NDA methylation diagnostic tool can differentiate cancerous cells with an accuracy of more than 95%. Furthermore, another major application is to diagnose early diagnose genetic diseases.

FIGURE 2: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Epigenetics Drugs and Diagnostic Technologies Application Insights

On the basis of application, the market of epigenetics drugs and diagnostic technologies segment into oncology, neurology, autoimmune diseases, and others. The oncology segment dominated the market in 2022, and neurology is projected to be the fastest-growing segment during the forecast period. DNA methylation plays an imperative role in diagnosing neurological diseases with precision, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. According to the Parkinson's Foundation, there were approximately 90,000 people diagnosed with Parkinson’s disease in the US in 2022.

Epigenetics Drugs and Diagnostic Technologies End User Insights

The market segmentation of epigenetics drugs and diagnostic technologies is based on end user, hospitals & clinics, diagnostic centers, and others, including academic & research institutes and ambulatory surgical centers. The hospitals & clinics segment dominated the market in 2022, and the diagnostic centers segment is projected to be the fastest-growing segment during the forecast period, i.e., 2022 to 2023. The factors influencing the growth of the end user are the increasing prevalence of chronic diseases such as cancer and neurology, raising awareness, and the wide range of applications of epigenetic diagnostic tools.

Epigenetics Drugs and Diagnostic Technologies Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. North America epigenetics drugs and diagnostic technologies market held the largest market share in 2022, due to the rising incidences of chronic diseases and the presence of major and active players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Pharmaceuticals, Inc. (US).

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's epigenetics drugs and diagnostic technologies market accounted for the second-largest market share due to the rising prevalence of genetic disorders and the launch of epigenetic tests to detect genetic disorders. In March 2019, the European Commission revealed that there are approximately 5.2 million births in Europe each year, and nearly 2.5% of people are born with congenital anomalies, a type of Down syndrome. Moreover, in April 2019, at the London Health Science Centre, a genome-wide DNA methylation test developed by a Canadian team was launched in European clinical laboratories. Furthermore, the Germany market of epigenetics drugs and diagnostic technologies held the largest market share in 2022, and the UK market of epigenetics drugs and diagnostic technologies is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific epigenetics drugs and diagnostic technologies market is expected to grow at a significant rate from 2023 to 2032, owing to the growing incidence of neurological diseases and increasing collaboration for the development of the drugs. As per the Alzheimer’s Disease International revealed in 2020, there are higher chances of Alzheimer’s in developing countries including China, India, South Asia, and Western Pacific neighbors due to the fastest growth of the geriatric population.

Furthermore, in January 2021, Celleron Therapeutics (UK) partnered with Nuance Biotech Ltd. (China) in order to develop a next-generation epigenetic immune regulator to target histone deacetylase to kill cancer. Additionally, it received approval from the Chinese Center for Drug Evaluation for a clinical trial of an investigational new drug (IND) registrational trial to develop CXD101 in patients suffering from peripheral T-cell lymphoma (PTCL). Moreover, the China market of epigenetics drugs and diagnostic technologies accounted for the largest market share, and the India market of epigenetics drugs and diagnostic technologies is projected to be the fastest-growing market in the Asia-Pacific region.

Epigenetics Drugs and Diagnostic Technologies Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of epigenetics drugs and diagnostic technologies grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the epigenetics drugs and diagnostic technologies industry must offer cost-effective products to expand and survive in an increasingly competitive and rising market environment.

Hologic, Inc. (Hologic) is engaged in manufacturing, developing, and supplying diagnostic products, surgical and medical imaging systems with prominence on women’s health. The company operates through four segments, including medical aesthetics, diagnostics, breast health, GYN surgical, and skeletal health.  The company has strong business presence in North America, Europe, Asia-Pacific, and Rest of the World. Moreover, in January 2021: the company acquired Diagenode Diagnostics (Belgium) for USD 159 million, a European molecular diagnostic company specialized in manufacturing and developing molecular diagnostic assays and epigenetic products.

Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies includes.

• Hologic, Inc. (US)


• Gilead Sciences, Inc. (US)


• Celleron Therapeutics (US)


• Illumina, Inc. (US)


• AstraZeneca PLC (UK)


• LISEN lmprinting Diagnostics (US)


• Salarius Pharmaceuticals, Inc. (US)


• Jubilant Therapeutics (US)


• Oryzon Genomics (Spain)


• Epiaxis Therapeutics (Australia)


• Others

Epigenetics Drugs and Diagnostic Technologies Industry Developments

• January 2021: Celleron Therapeutics (UK) partnered with Nuance Biotech Ltd. (China) in order to develop a next-generation epigenetic immune regulator to target histone deacetylase to kill cancer.


• January 2021: Hologic, Inc. (US) acquired Diagenode Diagnostics (Belgium) for USD 159 million, a European molecular diagnostic company specialized in manufacturing and developing molecular diagnostic assays and epigenetic products.

Epigenetics Drugs and Diagnostic Technologies Market Segmentation

Epigenetics Drugs and Diagnostic Technologies Drug Type Outlook

• DNA Methyltransferases (DNMTs) Inhibitors


• Histone Deacetylases (HDACs) Inhibitors


• Histone Methyltransferase (HMT) inhibitors


• Others

Epigenetics Drugs and Diagnostic Technologies Diagnostic Technologies Outlook

• DNA Methylation


• Histone Modification Analysis


• Others

Epigenetics Drugs and Diagnostic Technologies Application Outlook

• Oncology


• Neurology


• Autoimmune Diseases


• Others

Epigenetics Drugs and Diagnostic Technologies End User Outlook

• Hospitals & Clinics


• Diagnostic Centers


• Others

Epigenetics Drugs and Diagnostic Technologies Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America